Patent Assignment
Reel/Frame 053365/0342
Security Interest
Recorded: 2020-07-30
Pages: 12
Assignor
AMICUS THERAPEUTICS, INC.
Executed: 2020-07-30
Assignee
HAYFIN SERVICES LLP, AS AGENT
ONE EAGLE PLACE, LONDON, SW1Y6AF, UNITED KINGDOM
Covered Properties
(56)
Methods Of Enhancing And/Or Stabilizing Cardiac Function In Patients With Fabry Disease
Application:
16/642,620 →
Publication:
US US20200222377A1
Dosing Regimens For The Treatment Of Fabry Disease
Application:
16/806,404 →
Publication:
US US20200268890A1
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods for Treatment of Fabry Disease
Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases
Patent:
48,608 →
Application:
16/222,305 →
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Treatment of Fabry Disease in Ert-NaïVe and Ert-Experienced Patientn
Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The GLA Gene
Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene
Application:
62/883,756 →
Methods Of Treating Fabry Disease
Application:
62/972,392 →
Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene
Application:
62/986,297 →
Method for the Treatment of Pompe Disease Using 1-Deoxynojirimycin Derivatives
Dosing Regimens for the Treatment of Pompe Disease
Application:
14/398,210 →
Publication:
US US20150086530A1
High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease
Highly Potent Acid Alpha-Glucosidase with Enhanced Carbohydrates
Augmented Acid Alpha-Glucosidase for the Treatment of Pompe Disease
Method for Selection of High M6P Recombinant Proteins
Formulations Comprising Recombinant Acid Alpha-Glucosidase
Recombinant Human Acid Alpha-Glucosidase
Methods Of Treating Fabry Patients Having Renal Impairment
Methods of Treating Fabry Patients Having Renal Impairment
Drug Package
Patent:
843,850 →
Application:
29/585,388 →
Drug Package
Patent:
877,625 →
Application:
29/605,763 →
Drug Package
Patent:
867,162 →
Application:
29/684,830 →
Imino and Amino Sugar Purification
Assays for Diagnosing and Evaluating Treatment Options for Fabry Disease
Methods For Treatment of Fabry Disease
Methods for Treatment of Fabry Disease
Methods for Treatment of Fabry Disease
Methods for Treatment of Fabry Disease
Methods for Treatment of Fabry Disease
Method to Predict Response to Pharmacological Chaperone Treatment of Diseases
Method to Predict Response to Pharmacological Chaperone Treatment of Diseases
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The GLA Gene
Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The GLA Gene
Method for the treatment of Pompe disease using 1-deoxynojirimycin and derivatives
High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease
High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease
High Concentration Alpha-Glucosidase Compositions For The Treatment Of Pompe Disease
High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease
Highly Potent Acid Alpha-Glucosidase With Enhanced Carbohydrates
Method for Selection of High M6P Recombinant Proteins
Formulations Comprising Recombinant Acid Alpha-Glucosidase
Related Assignments
(10)
Other recorded transfers of the patents in this record — the chain of ownership.
Security Interest
Sep 28, 2018
From: AMICUS THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 047004/0208 →
Security Interest
May 11, 2020
From: AMICUS THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 052625/0916 →
Omnibus Confirmation of Assignment Agreement
May 21, 2020
From: BIOPHARMA CREDIT PLC
To: BPCR LIMITED PARTNERSHIP
Reel/Frame 052741/0173 →
Release of Security Interest
Jul 30, 2020
From: BPCR LIMITED PARTNERSHIP
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 053360/0659 →
Assignment of Assignor's Interest
Aug 5, 2022
From: CASTELLI, JEFF; BENJAMIN, ELFRIDA
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 061099/0803 →
Security Interest
Oct 6, 2023
From: AMICUS THERAPEUTICS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 065177/0196 →
Release of Security Interest
Oct 6, 2023
From: HAYFIN SERVICES LLP
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 065164/0945 →
Assignment of Assignor's Interest
Jul 11, 2024
From: CASTELLI, JEFF
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 067959/0418 →
Security Interest
Apr 27, 2026
From: BIOMARIN PHARMACEUTICAL INC.; AMICUS THERAPEUTICS, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075493/0968 →
Release of Security Interest
Apr 27, 2026
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 075494/0030 →